Controlled-release levodopa methyl ester/ benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Xinxin Yang; Ruiyuan Zheng; Yunpeng Cai; Meiling Liao; Weien Yuan; Zhenguo Liu
January 2012
International Journal of Nanomedicine;2012, Vol. 7, p2077
Academic Journal
No abstract available.


Related Articles

  • Levodopa.  // Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p25 

    The article presents two case studies of men diagnosed with levodopa-induced dyskinesias developed while receiving levodopa.

  • Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Picconi, Barbara; Bagetta, Vincenza; Ghiglieri, Veronica; Paillè, Vincent; Di Filippo, Massimiliano; Pendolino, Valentina; Tozzi, Alessandro; Giampà, Carmela; Fusco, Francesca R.; Sgobio, Carmelo; Calabresi, Paolo // Brain: A Journal of Neurology;Feb2011, Vol. 134 Issue 2, p375 

    The aim of the present study was to evaluate the role of the nitric oxide/cyclic guanosine monophosphate pathway in corticostriatal long-term depression induction in a model of levodopa-induced dyskinesia in experimental parkinsonism. Moreover, we have also analysed the possibility of targeting...

  • Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Bezard, Erwan; Ferry, Sandrine; Mach, Ulrich; Stark, Holger; Leriche, Ludovic; Boraud, Thomas; Gross, Christian; Sokoloff, Pierre // Nature Medicine;Jun2003, Vol. 9 Issue 6, p762 

    In monkeys rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), expression of the dopamine D[SUB3] receptor was decreased. However, levodopa-induced dyskinesia (LID), similar to the debilitating and pharmacoresistant involuntary movements elicited after long-term...

  • Levodopa.  // Reactions Weekly;May2014, Vol. 1503 Issue 1, p26 

    An abstract of the article "Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients," by M. Politis and colleagues is presented.

  • Levodopa.  // Reactions Weekly;9/7/2013, Issue 1468, p27 

    The article describes a case of levodopa-induced dyskinesia in a woman who was diagnosed with Parkinson's disease.

  • Does Levodopa Accelerate Parkinson's Disease? Simuni, T.; Stern, M.B. // Drugs & Aging;1999, Vol. 14 Issue 6, p399 

    Therapeutic options for the treatment of Parkinson's disease (PD) have expanded tremendously over the last 5 years, although levodopa remains the gold standard of therapy. A major therapeutic controversy has been the question of levodopa's potential to cause toxic effects on nigrostriatal cells,...

  • Levodopa.  // Reactions Weekly;10/5/2013, Issue 1472, p26 

    An abstract of the article "Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism," by P. Pita Lobo and colleagues is presented.

  • 1997 Royal College mealist in medicine.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS112 

    Presents an abstract of the research manuscript `Experimental investigation of levodopa-induced dyskinesia in a primate model of Parkinsonism,' by P.J. Blanchet.

  • Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias. Ahmed, Imtiaz; Bose, Subrata K.; Pavese, Nicola; Ramlackhansingh, Anil; Turkheimer, Federico; Hotton, Gary; Hammers, Alexander; Brooks, David J. // Brain: A Journal of Neurology;Apr2011, Vol. 134 Issue 4, p979 

    Levodopa-induced dyskinesias are a common complication of long-term therapy in Parkinson’s disease. Although both pre- and post-synaptic mechanisms seem to be implicated in their development, the precise physiopathology of these disabling involuntary movements remains to be fully...

  • NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. Mellone, Manuela; Stanic, Jennifer; Hernandez, Ledia F.; Iglesias, Elena; Zianni, Elisa; Longhi, Annalisa; Prigent, Annick; Picconi, Barbara; Calabresi, Paolo; Hirsch, Etienne C.; Obeso, Jose A.; Di Luca, Monica; Gardoni, Fabrizio // Frontiers in Cellular Neuroscience;Jul2015, Vol. 9, p1 

    Levodopa-induced dyskinesias (LIDs) are major complications in the pharmacological management of Parkinson's disease (PD). Abnormal glutamatergic transmission in the striatum is considered a key factor in the development of LIDs. This work aims at: (i) characterizing N-methyl-D-aspartate (NMDA)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics